



Excellent opportunity to acquire profitable, high quality drug product manufacturing operations, located in the USA and India, with significant ongoing supply contracts.

The Business

- ▶ Two stand-alone pharmaceutical manufacturing facilities:
 - Large scale oral dose formulation and filling facility in North America.
 - Regional scale combined primary (API) and secondary manufacturing facility in India.
- ▶ Top class management teams in both locations with many years' experience of major pharmaceutical company operations.



Key Assets and distinguishing capabilities

- ▶ Modern facilities in both sites.
- ▶ Sites capable of stand-alone operation.
- ▶ **US:**
 - Primary formulation of tablet, capsule and liquid oral dose products.
 - Warehousing and distribution capability for products made at site for North American market.
 - Broad experience in export shipping.
 - Significant capacity for expansion.
 - Capacity to manufacture over 2 billion tablets and capsules per year and over 8 million litres of solution and suspension products per year.
 - Fully licensed US controlled drugs site, including approved product storage.
 - Well-equipped pilot plant for secondary manufacturing.
- ▶ **India:**
 - Medium scale API manufacturing and integrated secondary manufacturing unit capable of making over 1 billion tablets per year and filling over 1 million bottles per year.
- ▶ Experienced and flexible workforce of approximately 350 people of whom two thirds are in North America.
- ▶ Comprehensive regulatory approvals with excellent compliance record, in particular both sites have received US FDA approvals. Sites also have significant experience in filing regulatory dossiers and launching products.
- ▶ Management experienced at managing integrated supply chain interactions with 3rd parties (CMO business) as both suppliers and customers.
- ▶ Expertise in technical product development as well as artwork and packaging development.
- ▶ Comprehensive site infrastructure with office building – ideal for head office.

Acquisition Opportunity

Opportunity for major geographic expansion into both the lucrative North American market and the Indian market from sites with broad regulatory approvals. Opportunity to leverage low costs of manufacture in India into sales in other markets. Services from US site could include packaging materials for clinical trials.

Current parent wishes to find a suitable buyer for long term strategic partnership, supplying key products to the parent under long term contracts.

For further information, please contact:

Jansen Jacob, Transactions Advisor
PharmaVentures Ltd., Florey House, Oxford Science Park
Oxford, OX4 4GP, UK

Direct: +44 (0)1865 332710 | **Mobile:** +44 (0)7951 205420

Switchboard: +44 (0)1865 332700

Email: jansen.jacob@pharmaventures.com